News | Radiation Therapy | August 27, 2019

PTW to Feature New Dosimetry Technology at ASTRO 2019

Offerings will include QA equipment for MR-guided and stereotactic therapy

Beamscan MR 3D water phantom – the first 3-D water phantom for magnetic resonance (MR)-guided radiotherapy

August 27, 2019 — Radiation dosimetry company PTW announced plans to exhibit its full range of radiation therapy dosimetry solutions for acceptance, commissioning, beam data acquisition and patient-specific quality assurance (QA) at the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-19 in Chicago.

In its booth, PTW will exhibit and demonstrate its latest solutions and most recent product developments including:

  • Beamscan MR 3D water phantom – the first 3-D water phantom for magnetic resonance (MR)-guided radiotherapy, available in two ready-to-use models for Elekta Unity and ViewRay MRIdian;
  • Beamscan 3D water phantom – fast to set up and easy to use for all acceptance testing and commissioning needs, now also available for the Halcyon system;
  • Starcheck maxi MR array – a comprehensive solution for machine QA, from high-resolution measurements up to 40 cm x 40 cm in magnetic fields to legally required documentation;
  • MR-conditional detectors – a wide range of PTW's detector brands that are now available for MR dosimetry;
  • Octavius 4-D modular patient and machine QA systems – for the latest radiotherapy techniques, including Halcyon, stereotactic radiosurgery (SRS) and MRgRT. Also introducing the Octavius Detector 1600 SRS for 3-D dose verification of complex SRS/SBRT (stereotactic body radiation therapy) treatment plans;
  • Ruby phantom – a new modular QA phantom with multiple inserts for comprehensive system QA, linear accelerator (linac) QA and patient QA;
  • microSilicon diode detector – the new silicon diode detector for small photon and all electron fields; and
  • Track-it 2.0 QA data management software – a versatile, web-based QA data management software that integrates QA data from different sources, devices and sites into a single platform.

For more information: www.ptwdosimetry.com

Related Content

Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Feature | Prostate Cancer | October 16, 2019 | By Jeff Zagoudis
Radiation therapy is an important tool in the clinician’s armamentarium for treatment of localized, early-stage prost
Videos | Radiation Oncology | October 11, 2019
Lorraine Drapek, DNP, nurse practitioner, radiation oncology, GI service,...
Patient Treatments With ViewRay's MRIdian Linac Begin in New England
News | Image Guided Radiation Therapy (IGRT) | October 08, 2019
ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac...
ProTom International received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radiance 330 proton therapy system
News | Proton Therapy | October 07, 2019
ProTom International received 510(k) clearance from the U.S.
Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Feature | ASTRO | October 03, 2019 | By Greg Freiherr
At the American Society for Radiation Oncology’s (ASTRO) 2019 a
Videos | Prostate Cancer | September 30, 2019
Bill Hartsell, M.D., medical director of the Northwestern Medicine Proton Center in Warrenville, Ill., discusses the
eBook on Hypofractionation in the Age of Value-based Care

eBook on Hypofractionation in the Age of Value-based Care

Sponsored Content | Case Study | Radiation Therapy | September 30, 2019
Hypofractionated and ultrahypofractionated radiation therapy — increasing dose per fraction to enable significantly f
AI Accurately Predicts Radiotherapy Side Effects for Head and Neck Cancer Patients
News | Artificial Intelligence | September 26, 2019
For the first time, a sophisticated computer model has been shown to accurately predict two of the most challenging...